Source comparison
The VEGF Upregulation Question — Theoretical Risk vs Observed Outcome
BPC-157's primary mechanism involves sustained upregulation of VEGF, the same growth factor targeted by anti-angiogenic cancer therapies like bevacizumab (Avastin). The theoretical concern is straightforward: if you're chronically increasing VEGF signaling, ar
This comparison does not assign a generated winner or score.
- BPC-157's primary mechanism involves sustained upregulation of VEGF, the same growth factor targeted by anti-angiogenic cancer therapies like bevacizumab (Avastin). The theoretical concern is straightforward: if you're chronically increasing VEGF signaling, are you creating an environment that supports tumour angiogenesis in pre-cancerous tissues? Rodent bpc-157 long term studies show no increased tumour incidence over 12 months, but rodents have fundamentally different cancer susceptibility profiles than humans. Their telomerase expression patterns, apoptotic thresholds, and immune checkpoint signaling differ markedly from primate models.
- A 2019 review in Frontiers in Pharmacology examined angiogenic peptides and noted that chronic VEGF elevation has been associated with increased capillary permeability, potential retinopathy progression, and atherosclerotic plaque destabilisation in cardiovascular disease populations. None of these outcomes have been studied in humans receiving BPC-157 beyond 90 days. The gap isn't evidence of harm. It's the absence of evidence either way, which supplement marketing conveniently ignores.
- Rodent Tendon Repair Model
- 12 months
- Wistar rats (n=60)
- Histological healing score, tensile strength
- None observed at 10 mcg/kg
- Metabolic rate 7× faster than humans; immune response differences
- Rodent Gastric Ulcer Model
- 6 months
- Sprague-Dawley rats (n=40)
- Ulcer healing index, mucosal inflammation markers
- None at doses up to 50 mcg/kg
- No cardiovascular or hormonal panels assessed long-term
- Human IBD Trial (Oral)
- 12 weeks
- Adults with Crohn's or UC (n=40)
- Endoscopic inflammation score reduction
- No serious adverse events
- No follow-up beyond 90 days; no vascular or oncogenic screening
- Human Musculoskeletal Pilot
- 8 weeks
- Athletes with Achilles tendinopathy (n=20)
- Pain reduction, ultrasound tendon thickness
- Mild injection site reaction (15%)
- Underpowered; no Phase III replication; no multi-year follow-up
- Rodent Cardiovascular Model
- Rats with induced myocardial infarction (n=50)
- Cardiac ejection fraction, fibrosis score
- None at 20 mcg/kg
- Human cardiac remodeling timelines differ significantly
- Bottom Line
- Human data stops at 12 weeks
- No Phase III trials exist
- Mechanism suggests benefit, but chronic safety unknown
- Rodent models show no toxicity, but translation uncertainty high